LCDI Analysis plan 1

Treatment sequencing and clinical pathway description for metastatic breast cancer

# Subgroup for initial study

ER positive HER2 negative locally advanced or metastatic breast cancer

# Purpose

Provide information as a basis for a submission to the NHS Lothian Formulary Committee for the adoption of a new class of drugs CDK 4/6 inhibitors (palbociclib, ribociclib, abemeciclib)

# Method

Clinical pathway description

# Question

What is the current clinical pathway for Systemic Anticancer Therapy (SACT) for patients with ER positive HER2 negative secondary breast cancer?

# Cohort definition

Patients registered on the NHS Lothian secondary breast cancer database between 1st Jan 2012 and 31st December 2017 with ER positive HER2 negative breast cancer

# Patient characteristics at diagnosis

* Age at diagnosis
* Presentation (de-novo, recurrent)
* If recurrent
	+ (Neo)adjuvant chemotherapy (anthracycline, taxane)
	+ (Neo)adjuvant endocrine therapy (tamoxifen, letrazole/anastrazole, exemestane)
		- Time from aromatase inhibitor discontinuation
* Co-morbidities
* Socioeconomic status
* Performance status
* Height, weight, body surface area

# Treatment pathway

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | 1st line | 2nd line | 3rd line | 4th line |
| Letrazole/anastrazole | % | % | % | % |
| Exemestane | % | % | % | % |
| Exemestane + everolimus |  |  |  |  |
| Fulvestrant | % | % | % | % |
| Tamoxifen | % | % | % | % |
| Chemotherapy | % | % | % | % |

* Use of CDK 4/6 inhibitors
* Clinical trial treatment

# Outcomes

Summarised for each drug from treatment initiation

* Toxicity
* Performance status
* Time to commencement of next line of systemic therapy
* Overall survival
* 30 day mortality
* 90 day mortality
* Death in hospital rates

# Healthcare Activity and Costs

Average per month of treatment

* Inpatient stays
* outpatient attendances
* day case attendances
* A&E attendances
* GP out of hours service use
* social care use
* procedures and investigations
* supportive medicines